drugset
drugset / Press release

Clinical Phase Ib, Pharmacodynamic effect study

2016-10-13 · Algiax Pharmaceuticals GmbH · original algiax.com ↗

AP-325 · regulatory

On December 10th 2015 Algiax got its approval from the German authorities (BfArM) to start the Phase Ib study entitled “Pharmacodynamic Effects of AP-325 in Healthy Male Subjects using the Intradermal (ID) Capsaicin and Pressure Pain Models”.

The release as fetched from its publisher. algiax.com ↗